Assistant professor in Physiology & Biophysics and UCI MIND faculty co-authored a paper in the journal Nature that reveals a mechanism for memory preservation. To read a summary of the article, visit Brain and Behavior Research Foundation Related posts: Dean LaFerla Named One of OC Business Journal’s OC500 The Orange County Business Journal named Frank LaFerla, PhD, Dean of the Charlie Dunlop School of Biological Sciences, as one of the OC500 for Education. Read the recognition here...| UCI MIND
Welcome to Orange County's Alzheimer's Disease Research Center at the UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND)| mind.uci.edu
There’s something powerful about gathering on a Saturday morning—sharing a warm breakfast, good conversation, and a collective purpose to learn and grow. That’s exactly what happened at New Hope Presbyterian Church in Anaheim, where parishioners and community members came together to talk about something often left unspoken: brain health and Alzheimer’s disease. A Partnership Rooted in Care With the Programs in Medical Education (PRIME) Leadership Education to Advance Doctoring – Af...| UCI MIND
Join us Thursday October 16, 2025 for a discussion with Dr. Christy Hom to celebrate Down Syndrome Awareness Month. We’ll chat about advances in the field of Alzheimer’s disease research in people with Down syndrome. Watch on YouTube or Facebook: YOUTUBE: https://www.youtube.com/watch?v=HnEDqkbeo4c FACEBOOK: https://www.facebook.com/events/1342523500869400 The post Thursday 10/16: Ask the Doc with Dr. Christy Hom appeared first on UCI MIND.| UCI MIND
Anyone who’s worried about Alzheimer’s disease should know about Doug Whitney. Doug is what researchers have coined an “escapee” of familial Alzheimer’s disease (FAD), the rare hereditary form of Alzheimer’s caused by inheriting mutations in one of three genes (APP, PSEN1, and PSEN2). But to many in the disease community Doug represents hope, hope brought through research participation. FAD mutations lead to an aggressive buildup of amyloid plaques in the brain. People with these ...| UCI MIND
On October 4, at UCI’s Brilliant Future campaign close event, Chancellor Howard Gillman announced that UCI MIND Leadership Council members Ann and Charlie Quilter and their family members Matt, Patty, Chris, and Patrick, have made a historic $50 million gift to support UCI MIND. This transformative contribution is the largest ever for UCI MIND and ranks among the most significant ever received by the campus, arriving at a critical moment in time. Older adults are the fastest growing segment...| UCI MIND
The post MIND Matters | Quarterly Newsletter | Summer 2025 appeared first on UCI MIND.| UCI MIND
Today in STAT, my colleague and friend, Dr. Jason Karlawish from the University of Pennsylvania Memory Center offers “The way we talk about dementia is about to change completely.” The history of dementia care is less than ideal. Patients struggle to be seen by specialists and many if not most are not even diagnosed. Nihilism is rampant and the resources available to most patients and families on the journey of living with dementia are inadequate. Few treatments have achieved approval for...| UCI MIND
The post Sharing Alzheimer’s Education to the Spanish-Speaking Community in Southern California appeared first on UCI MIND.| UCI MIND
Drs. Kevin Beier and Elizabeth Head, both faculty members of UCI MIND, along with co-investigators Drs. Liz Chrastil and Jing Zhang have been awarded a 4 year NIH grant to study how hyperexcitability in neurons in a unique brain region (the retrospenial cortex thought to be a candidate site where AD pathology begins) contributes to the development of behavioral deficits in 3 mouse models of AD and what the molecular mechanisms are that underlie this effect. To translate their results to AD in...| UCI MIND
UCI MIND is in the spotlight again with the announcement of large collaborative NIA grant to study LATE. Read the article in the UC Irvine News Related posts: MIND Matters | Quarterly Newsletter | Summer 2024 ... Two UCI researchers named as UCI MIND WAM at Cleveland Clinic Women’s initiative recipients Since 2017, UCI MIND has partnered with the Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic, founded by Maria Shriver, to fund the Women’s Initiative. The initiative provides ...| UCI MIND
This week NPR published an article describing the reactions of three scientists who learned and subsequently shared their APOE genetic results. What makes this story unique is the way these highly informed people responded to learning their results and their convergent paths of using this knowledge to help advance Alzheimer’s research. The three scientists discovered at various points in their life that they were homozygous for the e4 allele of the apolipoprotein E (APOE) gene. APOE codes...| UCI MIND
Postmortem neuropathological examination of brain tissue is considered the gold standard for understanding many neurological diseases, including Alzheimer’s disease and related dementias (ADRD). Although fluid and imaging biomarkers provide scientists and clinicians with valuable insights into the diseases of the brain, these measures are standardized with brain autopsy to give researchers direct evidence needed to confirm diagnoses, study disease processes, and develop future treatments. N...| UCI MIND
Dr. Vivek Swarup has been awarded an Alzheimer’s Association Research Grant to study oligodendrocyte dysfunction in Alzheimer’s disease (AD). Dr. Swarup writes that Alzheimer’s disease has long been thought of as a problem of nerve cells, but new evidence shows that support cells called oligodendrocytes (OLs) may also play a direct role in driving the disease. These cells help insulate and protect nerves, but in Alzheimer’s, they appear to malfunction and may even produce harmful amyl...| UCI MIND
The post Dr. Karen Lincoln Appointed Co-Chair of New State Council on Toxic Substance Control appeared first on UCI MIND.| UCI MIND
The post UCI MIND researchers identify natural compounds to remove harmful proteins associated with Alzheimer’s disease appeared first on UCI MIND.| UCI MIND
The post UCI MIND Investigators Featured in UCI News for New Study on Sex Differences in AD Pathology Among Individuals with Down Syndrome appeared first on UCI MIND.| UCI MIND
Related posts: MIND Matters | Quarterly Newsletter | Fall 2024 ...| UCI MIND
MIND Matters is a quarterly publication that aims to keep the community abreast of developments in research and happenings across the Institute| UCI MIND
Welcome to UCI MINDcast, UCI MIND’s new video and podcast library with up-to-date content on the latest in Alzheimer’s and dementia research, education and care!| UCI MIND
The Alzheimer’s Disease Parkinson’s Disease (ADPD) 2025 International Conference, held this year in Vienna, Austria, is an annual gathering for scientific experts and industry leaders in neurodegenerative diseases. This conference serves as a platform for sharing the latest scientific breakthroughs, clinical trial results, and innovative treatment strategies. With attendees from over 70 countries giving more than 1,200 poster presentations and 700 oral presentations, ADPD uniquely combine...| UCI MIND
Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND. The efficacy of donanemab in treating early Alzheimer’s disease in people with Mild Cognitive Impairment and mild dementia due to Alzheimer’s disease is largely agreed to...| UCI MIND
For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions is the careful consideration of the available scientific evidence, particularly from randomized clinical trials (RCTs) such as the recent lecanemab trial. Translating RCT results into patient-level decisions, however, can be challenging. This is because trial results tell us about the outcomes o...| UCI MIND
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab had been expected before the end of this month. Though data for donanemab’s ability to lower brain amyloid levels are convincing, the FDA had opted not to grant accelera...| UCI MIND
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new year, UCI MIND and the field of Alzheimer’s disease and related dementias (ADRD) research are abuzz with excitement about progress made and opportunities to further advance our field. At the end of 2023, we held our annual signature fundraising event, the December to Remember Gala. We honored Lauren Miller Rogen and Seth Rogen, the founders of H...| UCI MIND